Evidence map›Paper›PMID 35858916›Full record

ReviewMalaria journal2022

Lessons for improved COVID-19 surveillance from the scale-up of malaria testing strategies.

Genevieve Kerr, Leanne J Robinson, Tanya L Russell, Joanne Macdonald

Open access · goldAbstract readReview
In one paragraph

Review in Malaria journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Malaria: past, present, and future.Signal transduction and targeted therapy · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Genevieve KerrGenecology Research Centre, School of Science and Engineering, University of the Sunshine Coast, Sippy Downs, QLD, 4556, Australia.
Leanne J RobinsonBurnet Institute, Melbourne, VIC, Australia.
Tanya L RussellAustralian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia. tanya.russell@jcu.edu.au.ORCID http://orcid.org/0000-0002-0920-6844
Joanne MacdonaldGenecology Research Centre, School of Science and Engineering, University of the Sunshine Coast, Sippy Downs, QLD, 4556, Australia. joanne@biocifer.com.
Australian Institute of Tropical Health and Medicine · AUBurnet Institute · AUCommonwealth Scientific and Industrial Research Organisation · AUUniversity of the Sunshine Coast · AU

Funding

Bill and Melinda Gates Foundation OPP1140133
6 · The paper itself

Abstract

Effective control of infectious diseases is facilitated by informed decisions that require accurate and timely diagnosis of disease. For malaria, improved access to malaria diagnostics has revolutionized malaria control and elimination programmes. However, for COVID-19, diagnosis currently remains largely centralized and puts many low- and middle-income countries (LMICs) at a disadvantage. Malaria and COVID-19 are infectious diseases that share overlapping symptoms. While the strategic responses to disease control for malaria and COVID-19 are dependent on the disease ecologies of each disease, the fundamental need for accurate and timely testing remains paramount to inform accurate responses. This review highlights how the roll-out of rapid diagnostic tests has been fundamental in the fight against malaria, primarily within the Asia Pacific and along the Greater Mekong Subregion. By learning from the successful elements of malaria control programmes, it is clear that improving access to point-of-care testing strategies for COVID-19 will provide a suitable framework for COVID-19 diagnosis in not only the Asia Pacific, but all malarious countries. In malaria-endemic countries, an integrated approach to point-of-care testing for COVID-19 and malaria would provide bi-directional benefits for COVID-19 and malaria control, particularly due to their paralleled likeness of symptoms, infection control strategies and at-risk individuals. This is especially important, as previous disease pandemics have disrupted malaria control infrastructure, resulting in malaria re-emergence and halting elimination progress. Understanding and combining strategies may help to both limit disruptions to malaria control and support COVID-19 control.

Indexed as

COVID-19MalariaAsiaCOVID-19 TestingHumansPandemicsAsia PacificCOVID-19GMSLMICMalariaPlasmodiumRapid diagnostic testRDT

Identifiers

PMID35858916
PMCPMC9296766
OpenAlexW4285891252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.